Form 8-K · Current Report · Filed 2024-02-01
Revvity Announces Fourth Quarter and Full Year 2023 Financial Results
Revvity, Inc. announced its financial results for the fourth quarter and full year of 2023, reporting GAAP EPS of $0.64 for Q4 and $5.55 for the full year, compared to $1.01 and $4.50 in the same periods of 2022. The company reported a (6)% revenue decrease in Q4 and a (17)% decrease for the full year. Adjusted EPS for Q4 was $1.25 and $4.65 for the full year. Revvity also provided guidance for the full year 2024, forecasting total revenue of $2.79-$2.85 billion and adjusted earnings per share of $4.55-$4.75. The company attributed the declines to industry headwinds and the impact of the COVID-19 pandemic.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0001157523-24-000146
- CIK
- 0000031791
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$107.18
Next session
-1.5%
Since filing
+36.9%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVTY reporting the same item, with the next session's move:
Exhibits (1)
About Revvity Inc.
Revvity Inc. is a health science tools and diagnostics company that provides end-to-end solutions for research, development, testing, and clinical use. The company operates through two main segments: Life Sciences and Diagnostics, serving customers across pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations. Its portfolio includes reagents, consumables, assays, instruments, software, and specialized services that support workflows from discovery through diagnosis. Revvity focuses on areas such as translational multi-omics, biomarker identification, imaging, screening, detection, informatics, reproductive health, immunodiagnostics, and genomic testing. It also supports applications in rare disease testing, newborn screening, hereditary cancer, and broader clinical laboratory services. Based in Waltham, Massachusetts, Revvity plays an important role in the healthcare and life sciences ecosystem by helping researchers, clinicians, and laboratories generate and analyze data across a wide range of scientific and diagnostic applications.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.